North American testing capacity doubled.
MDS Pharma Services established its first central lab in the U.S. The new 15,000-sq-ft facility, located in North Brunswick, NJ, expands MDS Pharma Services’ capabilities in late-stage pharmaceutical testing. It also provides central lab support services for clinical trials. In addition to standard safety testing, the company reports that this facility provides esoteric testing, including molecular biology, molecular genetics, flow cytometry, and immunoassays.

“We established this lab to meet the growing demand from clients for a facility in the United States that offers both standard and complex testing to support the development of new treatments,” comments David Spaight, president. “This location is easily accessible to many pharmaceutical companies headquartered in the Northeastern United States. It can accommodate clients who conduct clinical trials in and outside thecountry.”

Previous articleNeurologix Completes First Gene Therapy Trial for Parkinson’s Disease
Next articleAgreement Potentially Worth $530-M Reached by Roche and InterMune